Search Result

Results for "

ROS1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Reactive Oxygen Species (ROS) (25) ROS Kinase (39) Akt (3) Anaplastic lymphoma kinase (ALK) (26) Apoptosis (19) Atg7 (1) Atg8/LC3 (1) Autophagy (11) Bacterial (1) Bcl-2 Family (3) BCRP (1) c-Met/HGFR (10) c-Myc (1) Caspase (2) CDK (1) Cholinesterase (ChE) (1) COX (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (1) Drug Isomer (1) EGFR (2) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (3) FAK (2) Ferroptosis (1) FGFR (1) FKBP (1) FLT3 (3) Fluorescent Dye (1) Fungal (2) Isotope-Labeled Compounds (6) JAK (1) JNK (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) NAMPT (1) p38 MAPK (3) Parasite (1) PARP (1) PDGFR (1) PGE synthase (1) PI3K (1) PPAR (1) Prostaglandin Receptor (1) PROTACs (1) Quinone Reductase (1) Reference Standards (6) RET (1) Sigma Receptor (1) Small Interfering RNA (siRNA) (3) SOD (1) STAT (2) TAM Receptor (1) Trk Receptor (8) VEGFR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (55) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (8) Metabolic Disease (4) Neurological Disease (3)
Click Chemistry:	Azide (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: ROS Kinase Reactive Oxygen Species (ROS)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12215

Lorlatinib 30+ Cited Publications PF-06463922	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-12678

Entrectinib 25+ Cited Publications NMS-E628; RXDX-101	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy	Cancer
Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-50878

Crizotinib Maximum Cited Publications 86 Publications Verification PF-02341066	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase	Cancer
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a *ROS1* inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-131003

Taletrectinib 2 Publications Verification DS-6051b; AB-106; IBI-344	ROS Kinase	Cancer
Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective *ROS1/NTRK* inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants ^[1] .

HY-103022

Repotrectinib 5+ Cited Publications TPX-0005	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
Repotrectinib (TPX-0005) is a potent *ROS1* (IC₅₀=0.07 nM) and TRK (IC₅₀=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC₅₀=1.01 nM). Repotrectinib has anti-cancer activity ^[1] .

HY-152292

Zidesamtinib NVL-520; NUV-520	ROS Kinase	Cancer
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC₅₀s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer ^[1].

HY-W015913S

Pyruvic acid-13C3 sodium 1 Publications Verification Sodium 2-oxopropanoate-13C3; Acetylformic acid-13C3 sodium	Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate- ¹³C₃ is the ¹³C-labeled Sodium 2-oxopropanoate. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-50878A

Crizotinib hydrochloride Maximum Cited Publications 86 Publications Verification PF-02341066 hydrochloride	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a **ROS proto-oncogene 1 (ROS1)** inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

HY-15514

Merestinib 5+ Cited Publications LY2801653	c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor	Cancer
Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (K_i=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC₅₀=11 nM), FLT3 (IC₅₀=7 nM), AXL (IC₅₀=2 nM), MERTK (IC₅₀=10 nM), TEK (IC₅₀=63 nM), ROS1, DDR1/2 (IC₅₀=0.1/7 nM) and MKNK1/2 (IC₅₀=7 nM) ^[1] .

HY-N0578

Apigenin 7-glucoside 5+ Cited Publications Apigenin-7-O-β-D-glucopyranoside; Cosmosiin; Apigetrin	Reactive Oxygen Species (ROS)	Cancer
Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-145574

Iruplinalkib WX-0593	Anaplastic lymphoma kinase (ALK) ROS Kinase BCRP Akt ERK STAT	Cancer
Iruplinalkib (WX-0593) is an orally active and selective *ALK/ROS1* inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC₅₀ between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter *MATE1, MATE2K, P-gp* and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer ^[1] .

HY-12215R

Lorlatinib (Standard) PF-06463922 (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (Standard) is the analytical standard of Lorlatinib. This product is intended for research and analytical applications. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Apoptosis	Cancer
APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies ^[1] .

HY-N2693

6,8-Diprenylorobol	Apoptosis Reactive Oxygen Species (ROS) Caspase Akt ERK JNK p38 MAPK Bcl-2 Family	Cancer
6,8-Diprenylorobol, a prenylated isoflavone, is a nature product that could be isolated from the leaves of Cudrania tricuspidata. 6,8-Diprenylorobol antiproliferative effect and induces apoptosis through activation of p53 and generation of ROS .

HY-15514A

Merestinib dihydrochloride 5+ Cited Publications LY2801653 dihydrochloride	c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor	Cancer
Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (K_i=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC₅₀=11 nM), FLT3 (IC₅₀=7 nM), AXL (IC₅₀=2 nM), MERTK (IC₅₀=10 nM), TEK (IC₅₀=63 nM), ROS1, DDR1/2 (IC₅₀=0.1/7 nM) and MKNK1/2 (IC₅₀=7 nM) ^[1] .

HY-B1106

Tetrahydroxyquinone 1 Publications Verification Tetrahydroxy-1,4-benzoquinone; Tetrahydroxybenzoquinone	Reactive Oxygen Species (ROS) Apoptosis	Cancer
Tetrahydroxyquinone (Tetrahydroxy-1,4-benzoquinone), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS) .

HY-159147

SIAIS039	PROTACs ROS Kinase Apoptosis	Cancer
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) ^[1].

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits *ROS* .

HY-50878S

Crizotinib-d5 PF-02341066-d₅	Anaplastic lymphoma kinase (ALK) c-Met/HGFR ROS Kinase Autophagy	Cancer
Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-RS12136

Ros1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ros1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ros1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ros1 Mouse Pre-designed siRNA Set A Ros1 Mouse Pre-designed siRNA Set A

HY-12678S1

Entrectinib-d8 NMS-E628-d₈; RXDX-101-d₈	Isotope-Labeled Compounds Autophagy Anaplastic lymphoma kinase (ALK) Trk Receptor ROS Kinase	Cancer
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice ^[1] .

HY-131003A

Taletrectinib free base DS-6051b free base; AB-106 free base; IBI-344 free base	ROS Kinase	Cancer
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective *ROS1/NTRK* inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants ^[1] .

HY-RS12137

ROS1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROS1 Rat Pre-designed siRNA Set A contains three designed siRNAs for ROS1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROS1 Rat Pre-designed siRNA Set A ROS1 Rat Pre-designed siRNA Set A

HY-RS12135

ROS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROS1 Human Pre-designed siRNA Set A contains three designed siRNAs for ROS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROS1 Human Pre-designed siRNA Set A ROS1 Human Pre-designed siRNA Set A

HY-112801

F-1	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
F-1 is a potent ALK and *ROS1* dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC₅₀s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK ^WT, ROS1 ^WT, ALK ^L1196M and ALK ^G1202R, respectively ^[1].

HY-160172

*ALK/ROS1-IN-4*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (example 13) is a dual inhibitor of ALK and ROS1 kinase ^[1].

HY-135509

Lorlatinib acetate PF-06463922 acetate	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
Lorlatinib (PF-06463922) acetate is a selective, orally active, brain-penetrant and ATP-competitive *ROS1/ALK* inhibitor with anticancer activity. Lorlatinib acetate has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK ^L1196M, respectively. Lorlatinib acetate targets to EML4-ALK, and inhibits ALK phosphorylation with IC₅₀s of 15-43 nM (ALK ^L1196), 14-80 nM (ALK ^G1269A), 38-50 nM (ALK ^1151Tins), 77-113 nM (ALK ^G1202R), respectively ^[1] .

HY-B1106A

Tetrahydroxyquinone monohydrate 1 Publications Verification Tetrahydroxy-1,4-benzoquinone monohydrate; Tetrahydroxybenzoquinone monohydrate	Reactive Oxygen Species (ROS) Apoptosis	Cancer
Tetrahydroxyquinone monohydrate (Tetrahydroxy-1,4-benzoquinone monohydrate), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone monohydrate can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS) .

HY-N10144

Shinpterocarpin	PI3K Akt Keap1-Nrf2 Bcl-2 Family SOD Reactive Oxygen Species (ROS)	Inflammation/Immunology
Shinpterocarpin is a flavonoid compound. Shinpterocarpin can be isolated from the air-dried roots of Glycyrrhiza glabra L. and Xuanshen Decoction. Shinpterocarpin binds to the targets PI3K, AKT, Nrf2, Bcl-2, Bax, CAT and SOD. Shinpterocarpin enhances immunity and exerts antioxidant effects by reducing the production of *ROS* .

HY-161975

ROS1-IN-2	ROS Kinase	Cancer
ROS1-IN-2 (Compound 3) is a *ROS1* inhibitor. ROS1-IN-2 can be used in the study of cancer ^[1].

HY-150974

ROS1-IN-1	ROS Kinase	Cancer
ROS1-IN-1 (Compound 31) is a potent and selective *ROS1* kinase inhibitor with an IC₅₀ of 0.097 μM ^[1].

HY-157391

*ALK/ROS1-IN-3*	ROS Kinase Anaplastic lymphoma kinase (ALK)	Cancer
ALK/ROS1-IN-3 (compound C01) is a *ROS1* and ALK dual inhibitor with IC₅₀s of 42.3 nM and 49.1 nM for ROS1 ^G2032R and ALK ^G1202R, respectively ^[1].

HY-178391

SMU-037	ROS Kinase p38 MAPK ERK Apoptosis	Cancer
SMU-037 is an orally active and selective *ROS1* inhibitor that demonstrates potent activity (IC₅₀ = 6.8 nM) and possesses the ability to penetrate the blood-brain barrier. SMU-037 shows ~25-fold selectivity over ALK, and superior sensitivity against the G2032R mutation. SMU-037 attenuates phosphorylation of ROS1 and downstream MAPK-ERK signaling pathway, leading to cell cycle arrest and apoptosis. SMU-037 effectively suppresses tumor progression in both xenograft and intracranial mouse models. SMU-037 can be used for non-small cell lung cancer (NSCLC) research ^[1].

HY-111416

WY-135	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
WY-135 is an ALK (IC₅₀=1.4 nM) and *ROS1* (IC₅₀=1.1 nM) dual inhibitor.

HY-170418

*ALK/ROS1-IN-5*	Anaplastic lymphoma kinase (ALK) ROS Kinase Apoptosis	Cancer
ALK/ROS1-IN-5 (compound X4) is a selective ALK and *ROS1* kinases inhibitor with IC₅₀s of 0.512 μM (ALK), 0.766 μM (ROS1), respectively. ALK/ROS1-IN-5 inhibits H2228 cells with an IC₅₀ of 0.034 μM. ALK/ROS1-IN-5 induces cancer cells apoptosis in dose-dependent manner. ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells_[1].

HY-160172A

*ALK/ROS1-IN-4 hydrate*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (hydrate) (example 13) is a dual inhibitor of ALK and ROS1 kinase ^[1].

HY-130794

*ALK/ROS1-IN-1*	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant *ALK/ROS1* dual inhibitor, with IC₅₀s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.

HY-176942

JYP0322 ROS1-IN-3	ROS Kinase Trk Receptor	Cancer
YP0322 (ROS1-IN-3) is a potent orally active, selective, and CNS-penetrant *ROS1* inhibitor. JYP0322 selectively inhibits human wild-type ROS1 and human ROS1 ^G2032R with IC₅₀s of 0.37 and 0.3 nM, respectively, showing 6-130-fold selectivity over TRKA, TRKB, and TRKC. JYP0322 inhibits proliferation of ROS1 fusion-expressing cells, and inhibits tumor growth in mouse xenograft models. JYP0322 can be used for the research of non-small cell lung cancer (NSCLC) ^[1].

HY-N7798

Pennogenin	Reactive Oxygen Species (ROS)	Inflammation/Immunology
Pennogenin is a bioactive component which can be isolated from T. govanianum rhizomes. Pennogenin exhibits significant in vitro inhibitory effect on release of ROS .

HY-W927359

Fluorescein hydrazide (3,6-Dihydroxyxanthane)	Fluorescent Dye	Others
Fluorescein hydrazide (3,6-Dihydroxyxanthane) is a fluorescein dye that can be used for the fluorophotometric determination of hydrogen peroxide (H2O2) and other reactive oxygen species (ROS) .

HY-12678R

Entrectinib (Standard) NMS-E628 (Standard); RXDX-101 (Standard)	Reference Standards ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy	Cancer
Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-12678S

Entrectinib-d4 NMS-E628-d₄; RXDX-101-d₄	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Isotope-Labeled Compounds	Cancer
Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, *ROS1* and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-50878AS

Crizotinib-d9 hydrochloride PF-02341066-d9 hydrochloride	c-Met/HGFR Autophagy Anaplastic lymphoma kinase (ALK) ROS Kinase Isotope-Labeled Compounds	Cancer
Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a **ROS proto-oncogene 1 (ROS1)** inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

HY-153743

Protein kinase inhibitor 4	ROS Kinase Trk Receptor	Cancer
Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and *ROS1* (IC₅₀=3.0 nM and 104 nM respectively) ^[1].

HY-N1306

Sideroxylin	Bacterial Reactive Oxygen Species (ROS) Apoptosis	Infection Cancer
Sideroxylin is a C-methylated flavone isolated from Callistemon lanceolatus and exerts antimicrobial activity against *Staphylococcus aureus. Sideroxylin inhibits ovarian cancer cell proliferation and induces apoptosis, causing DNA fragmentation, depolarization of the mitochondrial membrane, the generation of reactive oxygen species (ROS)* .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-N0578R

Apigenin 7-glucoside (Standard) Apigenin-7-O-β-D-glucopyranoside (Standard); Cosmosiin (Standard); Apigetrin (Standard)	Reference Standards Reactive Oxygen Species (ROS)	Cancer
Apigenin 7-glucoside (Standard) is the analytical standard of Apigenin 7-glucoside. This product is intended for research and analytical applications. Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-50878B

Crizotinib acetate PF-02341066 acetate	Anaplastic lymphoma kinase (ALK) ROS Kinase c-Met/HGFR	Cancer
Crizotinib (PF-02341066) acetate is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib acetate inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib acetate is also a *ROS1* inhibitor. Crizotinib acetate has effective tumor growth inhibition ^[1] .

HY-120387

SMU-B	ROS Kinase Anaplastic lymphoma kinase (ALK) TAM Receptor c-Met/HGFR	Cancer
SMU-B is the orally active inhibitor for ALK (IC₅₀<0.5 nM), *c-ros* oncogene 1** (ROS1), c-MET (IC₅₀=1.87 nM) and AXL (IC₅₀=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC₅₀s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models ^[1] .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

2,886 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Biochemical Assay Reagents
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Biochemical Assay Reagents
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Endogenous Metabolite
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-N0578

Apigenin 7-glucoside 5+ Cited Publications Apigenin-7-O-β-D-glucopyranoside; Cosmosiin; Apigetrin	Flavonoids Classification of Application Fields Flavones Dendranthema morifolium (Ramat.) Tzvel. Phenols Polyphenols Plants Compositae Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS)
Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-N2693

6,8-Diprenylorobol	Flavonoids Maclura tricuspidata Carriere Plants Moraceae Isoflavones Source Classification	Apoptosis Reactive Oxygen Species (ROS) Caspase Akt ERK JNK p38 MAPK Bcl-2 Family
6,8-Diprenylorobol, a prenylated isoflavone, is a nature product that could be isolated from the leaves of Cudrania tricuspidata. 6,8-Diprenylorobol antiproliferative effect and induces apoptosis through activation of p53 and generation of ROS .

HY-N7798

Pennogenin	Structural Classification Liliaceae Classification of Application Fields Trillium tschonoskii Maxim. Plants Inflammation/Immunology Disease Research Fields Steroids Source Classification	Reactive Oxygen Species (ROS)
Pennogenin is a bioactive component which can be isolated from T. govanianum rhizomes. Pennogenin exhibits significant in vitro inhibitory effect on release of ROS .

HY-N1306

Sideroxylin	Infection Eucalyptus saligna Flavonoids Classification of Application Fields Flavones Phenols Polyphenols Myrtaceae Plants Disease Research Fields Source Classification	Bacterial Reactive Oxygen Species (ROS) Apoptosis
Sideroxylin is a C-methylated flavone isolated from Callistemon lanceolatus and exerts antimicrobial activity against *Staphylococcus aureus. Sideroxylin inhibits ovarian cancer cell proliferation and induces apoptosis, causing DNA fragmentation, depolarization of the mitochondrial membrane, the generation of reactive oxygen species (ROS)* .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge *ROS* .

HY-N0578R

Apigenin 7-glucoside (Standard) Apigenin-7-O-β-D-glucopyranoside (Standard); Cosmosiin (Standard); Apigetrin (Standard)	Structural Classification Flavonoids Flavones Dendranthema morifolium (Ramat.) Tzvel. Phenols Polyphenols Plants Compositae Source Classification	Reference Standards Reactive Oxygen Species (ROS)
Apigenin 7-glucoside (Standard) is the analytical standard of Apigenin 7-glucoside. This product is intended for research and analytical applications. Apigenin-7-glucoside (Apigenin-7-O-β-D-glucopyranoside) exhibits significant anti-proliferative and antioxidant activity and scavenges reactive oxygen species (ROS) .

HY-N11887

Linocinnamarin	Natural Products Rosaceae Plants Source Classification Fragaria × ananassa Duch.	Reactive Oxygen Species (ROS)
Linocinnamarin is a nature product that could be isolated from Fragaria ananassa Duch. Linocinnamarin has anti-inflammatory activity. Linocinnamarin inhibits antigen-stimulated elevation of intracellular free Ca ²⁺ concentration and reactive oxygen species (ROS) .

Species:	Human (4)
Tag:	His (4) Strep (1) GST (2)
Source:	sf9 insect cells (1) Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702714

	ROS1 Protein, Human (Active, sf9, His) ROS1; ROS proto-oncogene 1, receptor tyROSine kinase; ROS; MCF3; c-ROS-1	Human	Sf9 insect cells
	ROS1 Protein, Human (sf9, His) is the recombinant human-derived ROS1, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P705880

	ROS1 Protein, Human (G2101A, sf9, His-Strep) ROS1; ROS proto-oncogene 1, receptor tyROSine kinase; ROS; MCF3; c-ROS-1	Human	sf9 insect cells

HY-P706095

	ROS1 Protein, Human (Active, G2032R, sf9, His-GST) Proto-oncogene tyROSine-protein kinase ROS; Proto-oncogene c-ROS; Proto-oncogene c-ROS-1; Receptor tyROSine kinase c-ROS oncogene 1; c-ROS receptor tyROSine kinase; MCF3; ROS	Human	Sf9 insect cells

HY-P706096

	ROS1 Protein, Human (Active, L2086F, sf9, His-GST) Proto-oncogene tyROSine-protein kinase ROS; Proto-oncogene c-ROS; Proto-oncogene c-ROS-1; Receptor tyROSine kinase c-ROS oncogene 1; c-ROS receptor tyROSine kinase; MCF3; ROS	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W015913S

Pyruvic acid-13C3 sodium 1 Publications Verification
Sodium 2-oxopropanoate- ¹³C₃ is the ¹³C-labeled Sodium 2-oxopropanoate. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-12678S1

Entrectinib-d8

Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice ^[1] .

HY-12678S

Entrectinib-d4

Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice ^[1] .

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition ^[1] .

HY-50878S1

Crizotinib-d8

Crizotinib-d₈ (PF-02341066-d₈) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-50878S2

Crizotinib-d9

Crizotinib-d₉ (PF-02341066-d₉) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition ^[1] .

HY-B0847S

Propiconazole-d7

Propiconazole-d₇ is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC₅₀s=0.04 and >200 μM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 μg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS) .

Host:	Mouse (1) Rabbit (1)
Reactivity:	Human (2)
Application:	IHC-P (2) WB (1)
Isotype:	IgG (1) IgG1 (1)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88018

	ROS1 Antibody (YA7703)	WB, IHC-P	Human
	ROS1 Antibody (YA7703) is a Mouse-derived and non-conjugated IgG1, monoclonal antibody, targeting to ROS1.

HY-P87054

	ROS1 Antibody (YA6747) c ROS 1 antibody; c ROS antibody; c ROS oncogene 1 receptor tyROSine kinase antibody; c ROS receptor tyROSine kinase antibody; c ROS1 antibody; MCF 3 antibody; MCF3 antibody; Oncogene ROS antibody; OTTHUMP00000017814 antibody; OTTHUMP00000017815 antibody; c ROS 1 antibody; c ROS antibody; c ROS oncogene 1 receptor tyROSine kinase antibody; c ROS receptor tyROSine kinase antibody; c ROS1 antibody; MCF 3 antibody; MCF3 antibody; Oncogene ROS antibody; OTTHUMP00000017814 antibody; OTTHUMP00000017815 antibody; OTTHUMP00000040389 antibody; Proto oncogene c ROS 1 protein antibody; Proto oncogene c ROS antibody; Proto oncogene tyROSine protein kinase ROS antibody; Proto oncogene tyROSine protein kinase ROS precursor antibody; Proto-oncogene c-ROS-1 antibody; Proto-oncogene tyROSine-protein kinase ROS antibody; Receptor tyROSine kinase c ROS oncogene 1 antibody; ROS 1 antibody; ROS 1C antibody; ROS antibody; ROS proto oncogene 1 , receptor tyROSine kinase antibody; ROS_HUMAN antibody; ROS1 antibody; ROS1C antibody; Transmembrane tyROSine specific protein kinase antibody; v ROS avian UR2 sarcoma virus oncogene homolog 1 antibody; v ROS UR2 sarcoma virus oncogene homolog 1 antibody;	IHC-P	Human
	ROS1 Antibody (YA6747) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ROS1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159147

SIAIS039		Azide
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ROS1

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products